Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D.

ABSTRACT: Affecting about 1 in 12 Americans annually, depression is a leading cause of the global disease burden. While a range of effective antidepressants are now available, failure and relapse rates remain substantial, with intolerable side effect burden the most commonly cited reason for discontinuation. Thus, understanding individual differences in susceptibility to antidepressant therapy side effects will be essential to optimize depression treatment. Here we perform genome-wide association studies (GWAS) to identify genetic variation influencing susceptibility to citalopram-induced side effects. The analysis sample consisted of 1762 depression patients, successfully genotyped for 421K single-nucleotide polymorphisms (SNPs), from the Sequenced Treatment Alternatives to Relieve Depression (STAR

SUBMITTER: Adkins DE 

PROVIDER: S-EPMC3410623 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature